Meeting
2023 ASCO Annual Meeting
Timing of immunotherapy-induced pneumonitis in patients with primary lung malignancy.
Authors
Megan Winter
Albert Einstein Medical Center, Philadelphia, PA
Megan Winter , Madiha Atif Gilani , Manasa Anipindi , Tejaswi Venigalla , Shriya Doreswamy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2647)
DOI
10.1200/JCO.2023.41.16_suppl.2647
Abstract #
2647
Poster Bd #
489
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).
First Author: Florian Guisier
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Poster
2022 ASCO Annual Meeting
Texture-based CT radiomics distinguishes radiation and immunotherapy induced pneumonitis in stage III NSCLC.
First Author: Lukas Delasos
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto